12 May 2020

In Lancet HIV RIHS researchers Angela Colbers and David Burger showed in an open-label, randomized controlled trial, that, when initiated in the 3rd trimester of pregnancy, achievement of VL <50cp/mL at delivery was more likely with dolutegravir-based therapy than with efavirenz-based regimens.

The trial was executed in Uganda and South Africa and we included 268 women living with HIV, diagnosed in late pregnancy. Our study addresses an important knowledge gap around antepartum transmission of HIV in women initiating treatment late in pregnancy. Dolutegravir was associated with higher rates of viral load reduction compared with efavirenz in pregnant women. Although both regimens were well tolerated by mothers and infants, more mothers who received dolutegravir developed serious adverse events (driven mainly by prolonged pregnancies) than did those who received efavirenz.
Our data support the revision to WHO guidelines recommending the transition to dolutegravir in first-line ART for all adults, regardless of pregnancy or child-bearing potential. The importance of the finding of more adverse events in mothers in the dolutegravir group is unclear and should be confirmed in other studies.

Learn more about DolPHIN-2

publication in Lancet HIV

Related news items

The European Hector Research Award in HIV 2021 awarded to Angela Colbers and David Burger

2 November 2021

On Friday 29 October 2021, during the 18th European AIDS Conference in London, the Hector Research Award for the best scientific article related to clinical or epidemiological HIV research was presented to Angela Colbers and David Burger, both working in the Pharmacy of the RadboudUMC.

read more

Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis

25 January 2021

Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.

read more

The effect of pregnancy on the pharmacokinetics of dolutegravir in women living with HIV

17 March 2020

In Clinical infectious diseases RIHS researchers Pauline Bollen, Jolien Freriksen, Angela Colbers and David Burger together with researchers of the PANNA network showed that dolutegravir use in pregnancy results in effective plasma concentrations.

read more

Importance of prospective studies in pregnant and breastfeeding women living with HIV

14 March 2019

In Clinical Infectious Diseases Angela Colbers, Stein Schalkwijk and David Burger give considerations on how to effectively evaluate aspects of clinical pharmacology required for safe and effective treatment to optimize pharmacotherapy during pregnancy and breastfeeding.

read more

Beyond the scientist: Roger Brüggemann

13 November 2018

Roger, who subscribed for the national pilot academy in 1992, eventually became a hospital pharmacist and associate professor of clinical pharmacology. This summer he became a “Cinglé du Ventoux”.

read more

Pharmacy receives prestigious European prize for research in Africa

27 September 2018

On 17 September, David Burger, professor of clinical pharmacy, together with colleagues from the United Kingdom, Uganda and Zimbabwe, received the "Outstanding Research Team" award from the European - Developing Countries Clinical Trial Partnership (EDCTP).

read more